Clinical Trial

Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）

Study acronym: SLE，SSc，RA
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）
Protocol Amendment History 4 changes
critical Phase changed: not applicable -> Phase 1 2026-04-10
critical Primary endpoint(s) modified 2026-04-10
notable Primary completion pushed: 2026-12-31 -> 2027-12-31 2026-04-10
minor Completion pushed: 2026-12-31 -> 2028-06-30 2026-04-10
Trial Details
NCT Number NCT06801119
Lead Sponsor Shenzhen MagicRNA Biotechnology Co., Ltd
Collaborators: The First Affiliated Hospital of University of Science and Technology of China
Conditions Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
Enrollment 30 participants
Start Date 2025-03-16
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12